Warning: The NCBI web site requires JavaScript to function. more...
Medical decision making for patients with Parkinson disease under Average Cost Criterion.
Goulionis JE, Vozikis A.
Aust New Zealand Health Policy. 2009 Jun 24;6:15.
Related citations
Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
Rubenstein LM, DeLeo A, Chrischilles EA.
Pharmacoeconomics. 2001;19(7):729-52. Review.
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.
A review of the health-related quality of life and economic impact of Parkinson's disease.
Dowding CH, Shenton CL, Salek SS.
Drugs Aging. 2006;23(9):693-721. Review.
The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.
Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, Thursz M, Russell I, Campbell M; REFLUX Trial Group.
Health Technol Assess. 2008 Sep;12(31):1-181, iii-iv.
Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV.
Curr Med Res Opin. 2008 Mar;24(3):753-68. Epub 2008 Jan 29.
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C, Burch J, Suekarran S, Walker S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Lorgelly P, Fenwick L, Palmer S.
Health Technol Assess. 2010 May;14(24):1-162. Review.
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.
Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.
Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. Review.
Cost of illness and its predictors for Parkinson's disease in Germany.
Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R.
Pharmacoeconomics. 2005;23(8):817-36.
Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ, Kaplitt MG, Stern MB, Eidelberg D.
Hum Gene Ther. 2001 Aug 10;12(12):1589-91.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Estimating the value of novel interventions for Parkinson's disease: an early decision-making model with application to dopamine cell replacement.
Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall O, Persson U, Hagell P.
Parkinsonism Relat Disord. 2006 Oct;12(7):443-52. Epub 2006 Jun 22.
Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ, Lees A, Apajasalo M, Pitkänen A, Turunen H.
Curr Med Res Opin. 2005 Jul;21(7):1005-14.
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
Health Technol Assess. 2001;5(32):1-195. Review.
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN, Luo MP, Chumney EC, King MS, Brun S.
Clin Drug Investig. 2007;27(1):67-74.
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. Review.
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP.
Pharmacoeconomics. 2004;22(6):389-411. Review.
Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, Gerstner A, Berger K, Hellwig D, Deuschl G, Freund HJ, Oertel WH, Dodel RC.
J Neurol. 2002 Jun;249(6):759-66.
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F, Lilliu H, Le Pen C.
Rev Neurol (Paris). 2001 May;157(5):507-14. French.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on